Press Releases

Shanghai, China, July 1, 2021 – WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, announced that it was awarded as a “Most Honored Company” of the 2021 All-Asia (ex-Japan) Executive Team rankings by Institutional Investor, an international financial publication, based on the strength of its outstanding corporate governance and investor relations management. WuXi Biologics also ranked first in five other award categories in Asia (pharmaceutical sector), including Best CEO, Best CFO, Best IR Professional, Best IR Program and Best ESG Company (Environmental, Social and Governance).

  As one of the most influential global financial publications, Institutional Investor is noted for the high-quality due diligence that goes into its award rankings. The publication covers 1,438 publicly-listed companies across 18 sectors in Asia. More than 4,000 portfolio managers and sell-side analysts participated in the voting for this year’s awards. The core evaluation factors included accessibility to senior executives, overall responsiveness, effectiveness of the IR team, timeliness of information disclosure, improvements made to corporate structure, and strength of ESG programs.

  This is the third consecutive year WuXi Biologics has received recognition by this publication and the capital markets it represents – a reaffirmation of the company’s strong leadership team and leading position in corporate governance, investor relations management, and ESG practices.

  Since being listed on the Hong Kong Stock Exchange in 2017, WuXi Biologics has remained committed to achieving the highest standards of capital market communication and corporate governance. Led by its experienced and dedicated management team, the company has taken a multichannel approach to ensure that shareholders and investors have timely access to its key business initiatives and strategies, while also actively practicing corporate social responsibility at all levels.

  To enable our global clients effectively fighting COVID-19, WuXi Biologics mobilized a world-class development and manufacturing team consisting of over 3,000 scientists. The company will deliver more than 800 kg neutralizing antibodies to treat over one million patients.

   “We create value for global investors by providing easy access, prompt response and transparent communication,” said Dr. Chris Chen, CEO of WuXi Biologics. “I’m very proud to see that our efforts have been recognized by the financial and investment communities. We will continue to improve information disclosure mechanisms and expand communication channels with global investors to create higher value for them along with stable business growth in the long term.”

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly one-stop service offering and strong value proposition to its global clients.

The company is currently conducting (as of March 22, 2021) a total of 361 integrated projects: 190 in pre-clinical development; 137 in early-phase (phase I and II) clinical development; 32 in late-phase (phase III) development; and 2 in commercial manufacturing. With a total estimated capacity at around 430,000 liters for biopharmaceutical production planned by 2024 in China, Ireland, the U.S., Germany, and Singapore, WuXi Biologics will provide its biomanufacturing partners with an even more robust and premier-quality global supply chain network.

  WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of its ethos and business strategy and has established an ESG committee led by the CEO to increase efficiency while advancing commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

  Contacts

  Media
PR@wuxibiologics.com

  Investors
IR@wuxibiologics.com